发布求助
文献互助 智能选刊 最新文献

Journal of the Advanced Practitioner in Oncology最新文献

筛选
英文 中文
Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer. 推进女性her2阳性转移性乳腺癌的护理。
Journal of the Advanced Practitioner in Oncology Pub Date : 2023-04-01 DOI: 10.6004/jadpro.2023.14.3.13
Marcie Beasley, Brooke Daniel
{"title":"Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer.","authors":"Marcie Beasley,&nbsp;Brooke Daniel","doi":"10.6004/jadpro.2023.14.3.13","DOIUrl":"https://doi.org/10.6004/jadpro.2023.14.3.13","url":null,"abstract":"<p><p>HER2 is overexpressed and/or amplified in approximately 20% of breast cancers. It is a clinically aggressive subtype; however, the introduction of targeted therapies has greatly improved survival rates. At JADPRO Live 2022, presenters discussed recent updates to clinical practice for HER2-positive metastatic breast cancer, and how to interpret emerging evidence on HER2-low data. They also highlighted best practices for monitoring and managing side effects for patients on these therapies.</p>","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 3","pages":"248-251"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c7/81/jadpro-14-248.PMC10184838.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9487462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Best Practices in the Management of Infectious Complications for Patients With Cancer: Management of Febrile Neutropenia. 癌症患者感染性并发症管理的最佳实践:发热性中性粒细胞减少症的管理。
Journal of the Advanced Practitioner in Oncology Pub Date : 2023-04-01 DOI: 10.6004/jadpro.2023.14.3.4
Kyle C Molina
{"title":"Best Practices in the Management of Infectious Complications for Patients With Cancer: Management of Febrile Neutropenia.","authors":"Kyle C Molina","doi":"10.6004/jadpro.2023.14.3.4","DOIUrl":"https://doi.org/10.6004/jadpro.2023.14.3.4","url":null,"abstract":"<p><p>Managing infection in patients with neutropenia is a difficult challenge, as fever is often the only clinical symptom. At JADPRO Live 2022, Kyle C. Molina, PharmD, BCIDP, AAVHIP, of the University of Colorado Hospital, discussed the epidemiology and pathophysiology associated with febrile neutropenia in patients with cancer. He reviewed appropriate treatment settings and empiric antimicrobial regimens for a patient and how to formulate a plan to safely de-escalate and target therapy for patients with febrile neutropenia.</p>","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 3","pages":"201-206"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/77/25/jadpro-14-201.PMC10184844.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9487466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2021-2022 Drug Updates in Solid Tumors. 2021-2022年实体肿瘤药物更新。
Journal of the Advanced Practitioner in Oncology Pub Date : 2023-04-01 DOI: 10.6004/jadpro.2023.14.3.9
Kirollos Hanna
{"title":"2021-2022 Drug Updates in Solid Tumors.","authors":"Kirollos Hanna","doi":"10.6004/jadpro.2023.14.3.9","DOIUrl":"https://doi.org/10.6004/jadpro.2023.14.3.9","url":null,"abstract":"<p><p>During JADPRO Live 2022, Kirollos Hanna, PharmD, BCPS, BCOP, briefed advanced practitioners on key FDA approvals from late 2021 to late 2022. He described mechanisms of action that are unique across some malignancies, as well as mechanisms of action that clinicians can utilize through an expanded indication or across other solid malignancies. Finally, he discussed safety profiles and what advanced practitioners can and should do in monitoring across solid tumors.</p>","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 3","pages":"227-231"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8f/36/jadpro-14-227.PMC10184837.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9858439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Managing the Patient With Multiple Primary Tumors. 多原发肿瘤患者的治疗。
Journal of the Advanced Practitioner in Oncology Pub Date : 2023-04-01 DOI: 10.6004/jadpro.2023.14.3.7
Holly Chitwood, Tamara Carey
{"title":"Managing the Patient With Multiple Primary Tumors.","authors":"Holly Chitwood,&nbsp;Tamara Carey","doi":"10.6004/jadpro.2023.14.3.7","DOIUrl":"https://doi.org/10.6004/jadpro.2023.14.3.7","url":null,"abstract":"<p><p>Multiple primaries are defined as more than one synchronous or metachronous cancer in the same individual. They can pose challenges to clinicians, as the goal is to find an anticancer therapy strategy that covers both cancer types without increased toxicity or drug interactions, and does not negatively impact a patient's overall outcome. At JADPRO Live 2022, presenters tackled this complicated topic by reviewing diagnostic criteria, epidemiology, and risk factors, demonstrating the prioritization of treatment, and discussing the role of the advanced practitioner in collaborative, interdisciplinary management of the patient with multiple primary tumors.</p>","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 3","pages":"218-221"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6b/03/jadpro-14-218.PMC10184849.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9858435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medical Aid in Dying: Ethical and Practical Issues. 临终医疗救助:伦理与实践问题。
Journal of the Advanced Practitioner in Oncology Pub Date : 2023-04-01 DOI: 10.6004/jadpro.2023.14.3.5
Jonathan Treem
{"title":"Medical Aid in Dying: Ethical and Practical Issues.","authors":"Jonathan Treem","doi":"10.6004/jadpro.2023.14.3.5","DOIUrl":"https://doi.org/10.6004/jadpro.2023.14.3.5","url":null,"abstract":"<p><p>At JADPRO Live 2022, Jonathan Treem, MD, of the University of Colorado Palliative Care, explained medical aid in dying in order to prepare advanced practitioners to feel confident to counsel a patient who inquiries about aid in dying. He explained the law and protocol for participation, the history, ethics, and data behind the intervention, and steps for what is required. Finally, Dr. Treem discussed ethical considerations that may arise as patients and clinicians consider these types of interventions.</p>","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 3","pages":"207-211"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c6/bf/jadpro-14-207.PMC10184842.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9858440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC. 转移性NSCLC患者靶向治疗模式的更新。
Journal of the Advanced Practitioner in Oncology Pub Date : 2023-04-01 DOI: 10.6004/jadpro.2023.14.3.12
Narjust Florez Duma, Stephanie Mcdonald
{"title":"Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC.","authors":"Narjust Florez Duma,&nbsp;Stephanie Mcdonald","doi":"10.6004/jadpro.2023.14.3.12","DOIUrl":"https://doi.org/10.6004/jadpro.2023.14.3.12","url":null,"abstract":"<p><p>The treatment paradigm for metastatic non-small cell lung cancer has changed significantly since the advent of targeted therapy. During JADPRO Live 2022, presenters focused on important updates to clinical practice guidelines, data from recent clinical trials of biomarkers and their respective targeted therapies, and best practices for monitoring and managing side effects associated with targeted therapies for metastatic non-small cell lung cancer.</p>","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 3","pages":"241-247"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/24/4f/jadpro-14-241.PMC10184836.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9858443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
JADPRO Live 2022: Reaching the Peak of Practice. JADPRO Live 2022:达到实践的顶峰。
Journal of the Advanced Practitioner in Oncology Pub Date : 2023-04-01 DOI: 10.6004/jadpro.2023.14.3.1
Beth Faiman
{"title":"JADPRO Live 2022: Reaching the Peak of Practice.","authors":"Beth Faiman","doi":"10.6004/jadpro.2023.14.3.1","DOIUrl":"https://doi.org/10.6004/jadpro.2023.14.3.1","url":null,"abstract":"<p><p>This special issue of JADPRO includes summaries of select educational sessions presented at JADPRO Live 2022.</p>","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 3","pages":"189-190"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/04/8d/jadpro-14-189.PMC10184843.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9484503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel Treatments for Patients With Relapsed/Refractory Multiple Myeloma. 复发/难治性多发性骨髓瘤患者的新疗法
Journal of the Advanced Practitioner in Oncology Pub Date : 2023-04-01 DOI: 10.6004/jadpro.2023.14.3.14
Cesar Rodriguez, Donna Catamero
{"title":"Novel Treatments for Patients With Relapsed/Refractory Multiple Myeloma.","authors":"Cesar Rodriguez,&nbsp;Donna Catamero","doi":"10.6004/jadpro.2023.14.3.14","DOIUrl":"https://doi.org/10.6004/jadpro.2023.14.3.14","url":null,"abstract":"<p><p>Therapeutic options for patients with multiple myeloma have multiplied in the past decade. However, multiple myeloma remains an incurable disease, and relapsed/refractory myeloma is characterized by genetic and cytogenetic alterations that drive resistance and result in progressively shorter durations of remission to each subsequent therapy. At JADPRO Live 2022, presenters discussed the multifactorial process for choosing the right therapy for a particular patient and strategies to manage unique treatment complications associated with novel treatment modalities used for patients with relapsed/refractory multiple myeloma.</p>","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 3","pages":"252-256"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c2/ad/jadpro-14-252.PMC10184840.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9487463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biomarker-Driven Oncology Clinical Trials: Novel Designs in the Era of Precision Medicine. 生物标志物驱动的肿瘤临床试验:精准医学时代的新设计。
Journal of the Advanced Practitioner in Oncology Pub Date : 2023-04-01 DOI: 10.6004/jadpro.2023.14.3.16
Donald C Moore, Andrew S Guinigundo
{"title":"Biomarker-Driven Oncology Clinical Trials: Novel Designs in the Era of Precision Medicine.","authors":"Donald C Moore,&nbsp;Andrew S Guinigundo","doi":"10.6004/jadpro.2023.14.3.16","DOIUrl":"https://doi.org/10.6004/jadpro.2023.14.3.16","url":null,"abstract":"<p><p>Oncology drug development historically has followed a path of sequential phase I, II, and III clinical trials using traditional trial designs, with the goal of achieving regulatory approval. These studies are often conducted with inclusion criteria that limit enrollment to a single tumor type or tumor site of origin, excluding other patients who might also respond. Increased use of precision medicine targeting biomarkers or specific oncogenic mutations has led to novel clinical trial designs that can evaluate these therapies in a less limited fashion. Master protocols such as basket trials, umbrella trials, and platform trials can, for example, evaluate histology-specific therapies targeting a common oncogenic mutation across multiple tumor types or screen for the presence of multiple different biomarkers rather than a single one. In other cases, they can lead to more rapid evaluation of a drug and evaluate targeted therapies in tumor types for which they are not yet currently indicated. As the use of complex biomarker-based master protocols increases, advanced practitioners must understand these novel trial designs, their advantages and disadvantages, and how their use may advance drug development and maximize the clinical benefits of molecular precision therapy.</p>","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 Suppl 1","pages":"9-13"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2f/5a/jadpro-14-9.PMC10190802.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9852822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Biomarker Pursuit: Keeping Current With Novel Biomarkers in Hematology/Oncology. 生物标志物的追求:在血液学/肿瘤学中保持最新的生物标志物。
Journal of the Advanced Practitioner in Oncology Pub Date : 2023-04-01 DOI: 10.6004/jadpro.2023.14.3.8
Beth Faiman, Sandra E Kurtin, Rasheda Persinger
{"title":"Biomarker Pursuit: Keeping Current With Novel Biomarkers in Hematology/Oncology.","authors":"Beth Faiman,&nbsp;Sandra E Kurtin,&nbsp;Rasheda Persinger","doi":"10.6004/jadpro.2023.14.3.8","DOIUrl":"https://doi.org/10.6004/jadpro.2023.14.3.8","url":null,"abstract":"<p><p>In the popular biomarker-focused session at JADPRO Live 2022, presenters paired biomarkers with tumor types for which their expression is most commonly used to determine targeted therapy, identified key assays used to measure common biomarkers, and reviewed recommendations and guidelines for biomarker testing.</p>","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 3","pages":"223-226"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b6/83/jadpro-14-223.PMC10184845.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9858442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信